alumis logo.png
Alumis Announces First Participant Dosed in Phase 1 Clinical Trial of CNS Penetrant Allosteric TYK2 Inhibitor A-005
April 30, 2024 08:00 ET | Alumis Inc
Alumis Inc. today announced that dosing has commenced in a Phase 1 clinical trial of A-005 in healthy participants.
alumis logo.png
Alumis to Participate in the 2024 Leerink Partners Global Biopharma Conference
March 11, 2024 09:00 ET | Alumis Inc
SOUTH SAN FRANCISCO, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Alumis Inc., a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to transform the lives of...
alumis logo.png
Alumis Presents Positive Data from Phase 2 Clinical Trial of ESK-001, an Oral Allosteric TYK2 Inhibitor for the Treatment of Plaque Psoriasis, at AAD Annual Meeting
March 09, 2024 12:00 ET | Alumis Inc
Alumis today announced the presentation of positive clinical data from a Phase 2 clinical trial of ESK-001 at AAD 2024.
alumis logo.png
Alumis Announces Upsized $259M Series C Financing to Advance Clinical-stage Pipeline of Oral Therapies Designed to Address Immune Dysfunction
March 06, 2024 08:00 ET | Alumis Inc
– Financing led by Foresite Capital, Samsara BioCapital and venBio Partners with participation from additional new and existing investors –      – Proceeds will support ongoing comprehensive mid to...
alumis logo.png
Alumis Announces Late-Breaker Psoriasis Phase 2 Data Presentation for Allosteric TYK2 Inhibitor ESK-001 at the American Academy of Dermatology 2024 Annual Meeting
March 04, 2024 09:00 ET | Alumis Inc
– Late-breaking oral presentation to highlight efficacy and safety of ESK-001 in a Phase 2 clinical trial and open label extension (OLE) study in adults with moderate-to-severe plaque psoriasis...
alumis logo.png
Alumis Presents Preclinical Data for Allosteric TYK2 Inhibitor A-005 at ACTRIMS
March 01, 2024 08:00 ET | Alumis Inc
– A-005 is a potential first-in-class, brain penetrant TYK2 inhibitor for the treatment of neuroinflammatory and neurodegenerative diseases – – Data support planned Phase 1 clinical trial on track to...
alumis logo.png
Alumis Announces Expansion of Allosteric TYK2 Inhibitor, ESK-001, Phase 2 Program into Systemic Lupus Erythematosus (SLE) and Uveitis
June 29, 2023 08:02 ET | Alumis Inc
– Patient dosing initiated in LUMUS, a 388 patient Phase 2b clinical trial of ESK-001 for the treatment of SLE – – Patient dosing initiated in OPTYK-1, a proof-of-concept clinical trial of ESK-001...